RecruitingNCT07030400

Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma

Predictors of Health-Related Quality of Life in Adults With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma


Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Enrollment

100 participants

Start Date

Jul 17, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The study aims to improve our understanding of how quality of life, fatigue, and symptoms change over 2 years when participants are treated for chronic lymphocytic leukemia or small lymphocytic lymphoma. We will compare two types of treatment to help future patients with chronic lymphocytic leukemia or small lymphocytic lymphoma know what to anticipate.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • All patients with pathology-confirmed diagnoses of CLL who are within seven days of starting treatment with a BTKi +/- an anti-CD 20 monoclonal antibody or BCL2i with Obinutuzumab treatment will be included.
  • Subjects must be able to read and speak English or Spanish at the 8th grade level.

Exclusion Criteria1

  • Patients with dementia, traumatic brain injury, or individuals with central nervous system involvement of their leukemia will be excluded from study participation.

Interventions

DRUGBruton's tyrosine kinase inhibitor

BTKi

DRUGB-Cell Lymphoma 2 Protein Inhibitor

BCL2i


Locations(1)

Moffitt Cancer Center

Tampa, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07030400


Related Trials